Photo Galleries

© GettyImages/Artur

NPD Gallery: Technology Insider

By Jane Byrne

We track developments and launches in process engineering tools and research components over the past few weeks.

© GettyImages/FlashMovie

NPD Gallery: Technology Insider

By Jane Byrne

We report on some of the latest biopharma industry targeted new releases in terms of technological innovation.

© GettyImages/kingwin

NPD Gallery: Technology Insider

By Jane Byrne

What's new in the world of biopharmaceutical tech this month? We track developments in process innovation equipment.


Hired and Retired: Gearing up for 2021

By Rachel Arthur

2020 has been an eventful year: but 2021 will also require skilful navigation. Here's some of the people who are stepping up to leading roles as we head into a new year.

© GettyImages/surasaki

Top five stories from October

By Jane Byrne

COVID-19 is like a big oak tree casting shade on all other biopharma industry developments. Vaccine-related articles dominate the most popular story rankings. With Pfizer and BioNTech now out in front in the coronavirus vaccine race, we track the related...

(Image: Getty/Natali Mis)

Hired and Retired: Jumping on gene therapy

By Ben Hargreaves

The gene therapy space is a rapidly developing areas in the industry, as a result those with expertise are finding their knowledge is invaluable to companies looking to advance in the space.

(Image: Getty/Rawpixel)

Hired and Retired: A summer of change

By Vassia Barba

As we have entered the summer, companies have taken to refreshing their leadership positions, including at companies such as Gilead, Alnylam, and Maze Therapeutics.

(Image: Getty/BrianAJackson)

Hired and Retired: The knock-on effect

By Ben Hargreaves & Maggie Lynch

BMS’ capture of Celgene caught much attention, due to the size and scale of the acqusition, but rival companies have taken the chance to snap up employees that have left after the deal.

(Image: Getty/Metamorworks)

Hired and Retired: Spring cleaning

By Ben Hargreaves

As we enter spring, several companies have refreshed the look of their executive boards – some to strengthen their direction and some out of necessity.

(Image: Getty/Gajus)

Hired and Retired: Pharma C-suites see new faces

By Maggie Lynch

While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.

(Image: Getty/Rawpixel)

Hired and Retired: Transitions at the top

By Ben Hargreaves

In a significant move at the larger end of the biopharma world, AstraZeneca’s global VP of cardiovascular, renal and metabolism made the move to Novo Nordisk to head up its biopharm unit.

(Image: Getty/Phototechno)

Hired and Retired: Big pharma to biotech trend continues

By Ben Hargreaves

As the stream of executives flowing from large pharma companies to smaller biotechs builds into a torrent, another month has passed with a number of significant switches. Notably, two former Genentech employees, responsible for work on some of its bestselling...

Inside Celltrion: a biosimilar success story built on landfill

Dispatches from Korea

Inside Celltrion: a biosimilar success story built on landfill

By Dan Stanton

Ambition, hard work and a focus on quality has made Celltrion the ‘pioneers of the mAb biosimilar industry,’ the firm told Biopharma-Reporter during a tour of its biomanufacturing site in Songdo, Korea.

BIO 2014: Photographs from inside the conference

BIO 2014: Photographs from inside the conference

By Zachary Brennan

Former Secretary of State and First Lady Hillary Clinton popped in for a long interview during one of the keynote luncheons to discuss all sorts of different topics with a BIO executive. The luncheon nicely complimented the international theme of the...

Taking a trip down to the 'Animal (Bio) Farm'


Taking a trip down to the 'Animal (Bio) Farm'

By Dan Stanton

Lab rats are not the only animals to play a role in bologics development as discovered when it donned its wellington boots and took a wonder down to the pharm...

Octapharma invites us 'truly human' Factor VIII plant

Octapharma invites BPR to 'truly human' Factor VIII plant

By Gareth Macdonald

Last year Octapharma filed the world’s first ‘truly human’ recombinant Factor VIII clotting protein for EMA review and invited to visit the Swedish site where it makes the haemophilia treatment using HEK cells.

Follow us


View more